2014 - 2016 Development of MR molecular imaging for brain amyloid detection: PET/MRI approach
2013 - 2016 Novel therapeutic strategy for amyotrophic lateral sclerosis targeting calretinin and monocyte chemoattractant protein-1
2014 - 2016 アルツハイマー病のインスリン抵抗性を標的とするアポモルフィン治療法の開発
2010 - 2015 Molecular pathology and regulatory mechanisms involved in the breakdown of nucleotide pool homeostasis under environmental stress
2010 - 2014 Evaluation of neuromuscular disease activity by diffusion tensor imaging
2010 - 2012 The influence of genetic polymorphism on preoperative platelet function testing in patients undergoing Carotid Artery Stenting
2010 - 2012 Development of multi-parametric MRI for preclinical diagnosis of Alzheimer's disease
2010 - 2012 アルツハイマー病の画期的アポモルフィン治療法開発
2008 - 2010 Early diagnosis and subtype classification of mild cognitive impairment using multimodal visual stimuli
2006 - 2007 アルツハイマー病における細胞内βアミロイド誘導性アポトーシスの抑止法開発
2004 - 2005 Epileptogenicity of neocortex in the novel rat model of focal cortical dysplasia
2002 - 2003 Analysis of the effect with the, expanded CTG repeat for cell toxicity, especially tauopathy in the central nervous system in patietnt of myotonic dystrophy type 1 (DM 1)
1994 - 1995 The presence of mutant HTLV-I in the central nervous system
Neurochemical research on Alzheimer's disease
Show all
Papers (239)：
Yasuharu Tabara, Yoko Okada, Masayuki Ochi, Yasumasa Ohyagi, Michiya Igase. One-leg standing time is a simple measure for loss of skeletal muscle mass and fat deposition in muscle: the J-SHIPP study. Aging clinical and experimental research. 2024. 36. 1. 7-7
Shiroh Miura, Emina Watanabe, Kensuke Senzaki, Shigeyoshi Hiruki, Sayaka Matsumoto, Takuya Morikawa, Yusuke Uchiyama, Seiji Kurata, Masayuki Ochi, Yasumasa Ohyagi, et al. Episodic ataxia type 2 with a novel missense variant (Leu602Arg) in CACNA1A. Human Genome Variation. 2024
Seiko Koizumi, Yoko Okada, Shiroh Miura, Yuuki Imai, Keiji Igase, Yasumasa Ohyagi, Michiya Igase. Ingestion of a collagen peptide containing high concentrations of prolyl-hydroxyproline and hydroxyprolyl-glycine reduces advanced glycation end products levels in the skin and subcutaneous blood vessel walls: a randomized, double-blind, placebo-controlled study. Bioscience, biotechnology, and biochemistry. 2023
